Pharmaceuticals - World Market Group of Eight (G8) Market Overview (Market size, Segmentation and Trends Analysis)
$ 1 495
- November 2012
- by MarketLine
- 182
Pharmaceuticals - Global Group of Eight (G8) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the G8 (United States, Canada, Germany, France, United Kingdom, Italy, Russia and Japan) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.
Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies
* Incorporates in-depth five forces competitive environment analysis and scorecards
* Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country. .
* Includes a five-year forecast of the industry
Highlights
The G8 countries contributed $534.8 billion in 2011 to the global pharmaceuticals industry, with a compound annual growth rate (CAGR) of 3.3% between 2007 and 2011. The G8 countries are expected to reach a value of $600.2 billion in 2016, with a CAGR of 2.3% over the 2011-16 period.
Among the G8 countries, the US holds the major share of the pharmaceuticals industry. It accounted for a share of 49.1% in 2011.
Among the G8 nations, the US is the leading country in the pharmaceuticals industry, with market revenues of $262.7 billion in 2011.
The US is expected to lead the pharmaceuticals industry in the G8 nations with a value of $299.5 billion in 2016.
Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
Market Definition
The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors).
Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.
TABLE OF CONTENTS
Introduction 16
What is this report about? 16
Who is the target reader? 16
How to use this report 16
Definitions 16
Group of Eight (G8) Pharmaceuticals Industry Outlook 17
Pharmaceuticals in Canada 21
Market Overview 21
Market Data 22
Market Segmentation 23
Market outlook 25
Five forces analysis 26
Macroeconomic indicators 34
Pharmaceuticals in France 36
Market Overview 36
Market Data 37
Market Segmentation 38
Market outlook 40
Five forces analysis 41
Macroeconomic indicators 49
Pharmaceuticals in Germany 51
Market Overview 51
Market Data 52
Market Segmentation 53
Market outlook 55
Five forces analysis 56
Macroeconomic indicators 64
Pharmaceuticals in Italy 66
Market Overview 66
Market Data 67
Market Segmentation 68
Market outlook 70
Five forces analysis 71
Macroeconomic indicators 79
Pharmaceuticals in Japan 81
Market Overview 81
Market Data 82
Market Segmentation 83
Market outlook 85
Five forces analysis 86
Macroeconomic indicators 94
Pharmaceuticals in Russia 96
Market Overview 96
Market Data 97
Market Segmentation 98
Market outlook 100
Five forces analysis 101
Macroeconomic indicators 109
Pharmaceuticals in The United Kingdom 111
Market Overview 111
Market Data 112
Market Segmentation 113
Market outlook 115
Five forces analysis 116
Macroeconomic indicators 124
Pharmaceuticals in The United States 126
Market Overview 126
Market Data 127
Market Segmentation 128
Market outlook 130
Five forces analysis 131
Macroeconomic indicators 139
Company Profiles 141
Leading companies 141
Appendix 183
Methodology 183
LIST OF TABLES
Table 1: G8 pharmaceuticals industry, revenue($bn), 2007-16 16
Table 2: G8 Pharmaceuticals industry, revenue by country (%), 2011 17
Table 3: G8 pharmaceuticals industry, revenue by country ($bn), 2007-11 18
Table 4: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2011-16 19
Table 5: Canada pharmaceuticals market value: $ billion, 2007–11 21
Table 6: Canada pharmaceuticals market geography segmentation: $ billion, 2011 22
Table 7: Canada pharmaceuticals market share: % share, by value, 2011 23
Table 8: Canada pharmaceuticals market value forecast: $ billion, 2011–16 24
Table 9: Canada size of population (million), 2007–11 33
Table 10: Canada gdp (constant 2000 prices, $ billion), 2007–11 33
Table 11: Canada gdp (current prices, $ billion), 2007–11 33
Table 12: Canada inflation, 2007–11 34
Table 13: Canada consumer price index (absolute), 2007–11 34
Table 14: Canada exchange rate, 2007–11 34
Table 15: France pharmaceuticals market value: $ billion, 2007–11 36
Table 16: France pharmaceuticals market geography segmentation: $ billion, 2011 37
Table 17: France pharmaceuticals market share: % share, by value, 2011 38
Table 18: France pharmaceuticals market value forecast: $ billion, 2011–16 39
Table 19: France size of population (million), 2007–11 48
Table 20: France gdp (constant 2000 prices, $ billion), 2007–11 48
Table 21: France gdp (current prices, $ billion), 2007–11 48
Table 22: France inflation, 2007–11 49
Table 23: France consumer price index (absolute), 2007–11 49
Table 24: France exchange rate, 2007–11 49
Table 25: Germany pharmaceuticals market value: $ billion, 2007–11 51
Table 26: Germany pharmaceuticals market geography segmentation: $ billion, 2011 52
Table 27: Germany pharmaceuticals market share: % share, by value, 2011 53
Table 28: Germany pharmaceuticals market value forecast: $ billion, 2011–16 54
Table 29: Germany size of population (million), 2007–11 63
Table 30: Germany gdp (constant 2000 prices, $ billion), 2007–11 63
Table 31: Germany gdp (current prices, $ billion), 2007–11 63
Table 32: Germany inflation, 2007–11 64
Table 33: Germany consumer price index (absolute), 2007–11 64
Table 34: Germany exchange rate, 2007–11 64
Table 35: Italy pharmaceuticals market value: $ billion, 2007–11 66
Table 36: Italy pharmaceuticals market geography segmentation: $ billion, 2011 67
Table 37: Italy pharmaceuticals market share: % share, by value, 2011 68
Table 38: Italy pharmaceuticals market value forecast: $ billion, 2011–16 69
Table 39: Italy size of population (million), 2007–11 78
Table 40: Italy gdp (constant 2000 prices, $ billion), 2007–11 78
Table 41: Italy gdp (current prices, $ billion), 2007–11 78
Table 42: Italy inflation, 2007–11 79
Table 43: Italy consumer price index (absolute), 2007–11 79
Table 44: Italy exchange rate, 2007–11 79
Table 45: Japan pharmaceuticals market value: $ billion, 2007–11 81
Table 46: Japan pharmaceuticals market geography segmentation: $ billion, 2011 82
Table 47: Japan pharmaceuticals market share: % share, by value, 2011 83
Table 48: Japan pharmaceuticals market value forecast: $ billion, 2011–16 84
Table 49: Japan size of population (million), 2007–11 93
Table 50: Japan gdp (constant 2000 prices, $ billion), 2007–11 93
Table 51: Japan gdp (current prices, $ billion), 2007–11 93
Table 52: Japan inflation, 2007–11 94
Table 53: Japan consumer price index (absolute), 2007–11 94
Table 54: Japan exchange rate, 2007–11 94
Table 55: Russia pharmaceuticals market value: $ billion, 2007–11 96
Table 56: Russia pharmaceuticals market geography segmentation: $ billion, 2011 97
Table 57: Russia pharmaceuticals market share: % share, by value, 2011 98
Table 58: Russia pharmaceuticals market value forecast: $ billion, 2011–16 99
Table 59: Russia size of population (million), 2007–11 108
Table 60: Russia gdp (constant 2000 prices, $ billion), 2007–11 108
Table 61: Russia gdp (current prices, $ billion), 2007–11 108
Table 62: Russia inflation, 2007–11 109
Table 63: Russia consumer price index (absolute), 2007–11 109
Table 64: Russia exchange rate, 2007–11 109
Table 65: United Kingdom pharmaceuticals market value: $ billion, 2007–11 111
Table 66: United Kingdom pharmaceuticals market geography segmentation: $ billion, 2011 112
Table 67: United Kingdom pharmaceuticals market share: % share, by value, 2011 113
Table 68: United Kingdom pharmaceuticals market value forecast: $ billion, 2011–16 114
Table 69: United Kingdom size of population (million), 2007–11 123
Table 70: United Kingdom gdp (constant 2000 prices, $ billion), 2007–11 123
Table 71: United Kingdom gdp (current prices, $ billion), 2007–11 123
Table 72: United Kingdom inflation, 2007–11 124
Table 73: United Kingdom consumer price index (absolute), 2007–11 124
Table 74: United Kingdom exchange rate, 2007–11 124
Table 75: United States pharmaceuticals market value: $ billion, 2007–11 126
Table 76: United States pharmaceuticals market geography segmentation: $ billion, 2011 127
Table 77: United States pharmaceuticals market share: % share, by value, 2011 128
Table 78: United States pharmaceuticals market value forecast: $ billion, 2011–16 129
Table 79: United States size of population (million), 2007–11 138
Table 80: United States gdp (constant 2000 prices, $ billion), 2007–11 138
Table 81: United States gdp (current prices, $ billion), 2007–11 138
Table 82: United States inflation, 2007–11 139
Table 83: United States consumer price index (absolute), 2007–11 139
Table 84: United States exchange rate, 2007–11 139
Table 85: Johnson & Johnson: key facts 140
Table 86: Johnson & Johnson: key financials ($) 141
Table 87: Johnson & Johnson: key financial ratios 141
Table 88: Pfizer Inc.: key facts 143
Table 89: Pfizer Inc.: key financials ($) 144
Table 90: Pfizer Inc.: key financial ratios 144
Table 91: AstraZeneca PLC: key facts 146
Table 92: AstraZeneca PLC: key financials ($) 147
Table 93: AstraZeneca PLC: key financial ratios 148
Table 94: GlaxoSmithKline Plc: key facts 150
Table 95: GlaxoSmithKline Plc: key financials ($) 151
Table 96: GlaxoSmithKline Plc: key financials (£) 152
Table 97: GlaxoSmithKline Plc: key financial ratios 152
Table 98: Novartis AG: key facts 154
Table 99: Novartis AG: key financials ($) 155
Table 100: Novartis AG: key financial ratios 155
Table 101: Chiesi Farmaceutici S.P.A.: key facts 157
Table 102: Menarini Group, The: key facts 159
Table 103: Takeda Pharmaceutical Company Limited: key facts 160
Table 104: Takeda Pharmaceutical Company Limited: key financials ($) 161
Table 105: Takeda Pharmaceutical Company Limited: key financials (¥) 161
Table 106: Takeda Pharmaceutical Company Limited: key financial ratios 161
Table 107: Daiichi Sankyo Co., Ltd.: key facts 163
Table 108: Daiichi Sankyo Co., Ltd.: key financials ($) 164
Table 109: Daiichi Sankyo Co., Ltd.: key financials (¥) 164
Table 110: Daiichi Sankyo Co., Ltd.: key financial ratios 164
Table 111: Mitsubishi Tanabe Pharma Corporation: key facts 166
Table 112: Mitsubishi Tanabe Pharma Corporation: key financials ($) 167
Table 113: Mitsubishi Tanabe Pharma Corporation: key financials (¥) 167
Table 114: Mitsubishi Tanabe Pharma Corporation: key financial ratios 167
Table 115: Pharmstandard OJSC: key facts 169
Table 116: Pharmstandard OJSC: key financials ($) 169
Table 117: Pharmstandard OJSC: key financials (RUB) 170
Table 118: Pharmstandard OJSC: key financial ratios 170
Table 119: Sanofi: key facts 172
Table 120: Sanofi: key financials ($) 173
Table 121: Sanofi: key financials (€) 173
Table 122: Sanofi: key financial ratios 173
Table 123: Bayer AG: key facts 175
Table 124: Bayer AG: key financials ($) 176
Table 125: Bayer AG: key financials (€) 176
Table 126: Bayer AG: key financial ratios 177
Table 127: Merck & Co., Inc.: key facts 179
Table 128: Merck & Co., Inc.: key financials ($) 180
Table 129: Merck & Co., Inc.: key financial ratios 180
LIST OF FIGURES
Figure 1: G8 pharmaceuticals industry, revenue($bn), 2007-16 15
Figure 2: G8 pharmaceuticals industry, revenue by country ($bn), 2007-11 17
Figure 3: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2011-16 18
Figure 4: Canada pharmaceuticals market value: $ billion, 2007–11 20
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2011 21
Figure 6: Canada pharmaceuticals market share: % share, by value, 2011 22
Figure 7: Canada pharmaceuticals market value forecast: $ billion, 2011–16 23
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2011 24
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2011 25
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2011 27
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2011 28
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2011 30
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2011 31
Figure 14: France pharmaceuticals market value: $ billion, 2007–11 35
Figure 15: France pharmaceuticals market geography segmentation: % share, by value, 2011 36
Figure 16: France pharmaceuticals market share: % share, by value, 2011 37
Figure 17: France pharmaceuticals market value forecast: $ billion, 2011–16 38
Figure 18: Forces driving competition in the pharmaceuticals market in France, 2011 39
Figure 19: Drivers of buyer power in the pharmaceuticals market in France, 2011 40
Figure 20: Drivers of supplier power in the pharmaceuticals market in France, 2011 42
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2011 43
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2011 45
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in France, 2011 46
Figure 24: Germany pharmaceuticals market value: $ billion, 2007–11 50
Figure 25: Germany pharmaceuticals market geography segmentation: % share, by value, 2011 51
Figure 26: Germany pharmaceuticals market share: % share, by value, 2011 52
Figure 27: Germany pharmaceuticals market value forecast: $ billion, 2011–16 53
Figure 28: Forces driving competition in the pharmaceuticals market in Germany, 2011 54
Figure 29: Drivers of buyer power in the pharmaceuticals market in Germany, 2011 55
Figure 30: Drivers of supplier power in the pharmaceuticals market in Germany, 2011 57
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2011 58
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2011 60
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2011 61
Figure 34: Italy pharmaceuticals market value: $ billion, 2007–11 65
Figure 35: Italy pharmaceuticals market geography segmentation: % share, by value, 2011 66
Figure 36: Italy pharmaceuticals market share: % share, by value, 2011 67
Figure 37: Italy pharmaceuticals market value forecast: $ billion, 2011–16 68
Figure 38: Forces driving competition in the pharmaceuticals market in Italy, 2011 69
Figure 39: Drivers of buyer power in the pharmaceuticals market in Italy, 2011 70
Figure 40: Drivers of supplier power in the pharmaceuticals market in Italy, 2011 72
Figure 41: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2011 73
Figure 42: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2011 75
Figure 43: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2011 76
Figure 44: Japan pharmaceuticals market value: $ billion, 2007–11 80
Figure 45: Japan pharmaceuticals market geography segmentation: % share, by value, 2011 81
Figure 46: Japan pharmaceuticals market share: % share, by value, 2011 82
Figure 47: Japan pharmaceuticals market value forecast: $ billion, 2011–16 83
Figure 48: Forces driving competition in the pharmaceuticals market in Japan, 2011 84
Figure 49: Drivers of buyer power in the pharmaceuticals market in Japan, 2011 85
Figure 50: Drivers of supplier power in the pharmaceuticals market in Japan, 2011 87
Figure 51: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2011 88
Figure 52: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2011 90
Figure 53: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2011 91
Figure 54: Russia pharmaceuticals market value: $ billion, 2007–11 95
Figure 55: Russia pharmaceuticals market geography segmentation: % share, by value, 2011 96
Figure 56: Russia pharmaceuticals market share: % share, by value, 2011 97
Figure 57: Russia pharmaceuticals market value forecast: $ billion, 2011–16 98
Figure 58: Forces driving competition in the pharmaceuticals market in Russia, 2011 99
Figure 59: Drivers of buyer power in the pharmaceuticals market in Russia, 2011 100
Figure 60: Drivers of supplier power in the pharmaceuticals market in Russia, 2011 102
Figure 61: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2011 103
Figure 62: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2011 105
Figure 63: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2011 106
Figure 64: United Kingdom pharmaceuticals market value: $ billion, 2007–11 110
Figure 65: United Kingdom pharmaceuticals market geography segmentation: % share, by value, 2011 111
Figure 66: United Kingdom pharmaceuticals market share: % share, by value, 2011 112
Figure 67: United Kingdom pharmaceuticals market value forecast: $ billion, 2011–16 113
Figure 68: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2011 114
Figure 69: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2011 115
Figure 70: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2011 117
Figure 71: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2011 118
Figure 72: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2011 120
Figure 73: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2011 121
Figure 74: United States pharmaceuticals market value: $ billion, 2007–11 125
Figure 75: United States pharmaceuticals market geography segmentation: % share, by value, 2011 126
Figure 76: United States pharmaceuticals market share: % share, by value, 2011 127
Figure 77: United States pharmaceuticals market value forecast: $ billion, 2011–16 128
Figure 78: Forces driving competition in the pharmaceuticals market in the United States, 2011 129
Figure 79: Drivers of buyer power in the pharmaceuticals market in the United States, 2011 130
Figure 80: Drivers of supplier power in the pharmaceuticals market in the United States, 2011 132
Figure 81: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2011 133
Figure 82: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2011 135
Figure 83: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2011 136
Figure 84: Johnson & Johnson: revenues & profitability 140
Figure 85: Johnson & Johnson: assets & liabilities 141
Figure 86: Pfizer Inc.: revenues & profitability 144
Figure 87: Pfizer Inc.: assets & liabilities 144
Figure 88: AstraZeneca PLC: revenues & profitability 147
Figure 89: AstraZeneca PLC: assets & liabilities 148
Figure 90: GlaxoSmithKline Plc: revenues & profitability 151
Figure 91: GlaxoSmithKline Plc: assets & liabilities 152
Figure 92: Novartis AG: revenues & profitability 155
Figure 93: Novartis AG: assets & liabilities 155
Figure 94: Takeda Pharmaceutical Company Limited: revenues & profitability 161
Figure 95: Takeda Pharmaceutical Company Limited: assets & liabilities 161
Figure 96: Daiichi Sankyo Co., Ltd.: revenues & profitability 164
Figure 97: Daiichi Sankyo Co., Ltd.: assets & liabilities 164
Figure 98: Mitsubishi Tanabe Pharma Corporation: revenues & profitability 167
Figure 99: Mitsubishi Tanabe Pharma Corporation: assets & liabilities 167
Figure 100: Pharmstandard OJSC: revenues & profitability 169
Figure 101: Pharmstandard OJSC: assets & liabilities 170
Figure 102: Sanofi: revenues & profitability 173
Figure 103: Sanofi: assets & liabilities 173
Figure 104: Bayer AG: revenues & profitability 176
Figure 105: Bayer AG: assets & liabilities 177
Figure 106: Merck & Co., Inc.: revenues & profitability 179
Figure 107: Merck & Co., Inc.: assets & liabilities 180
Pharmaceutical in Europe
- $ 250
- Industry data
- January 2013
Yearly, From 2003 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu
- Industries : Pharmaceutical
- Countries : Portugal, Europe
- $ 250
- Industry data
- January 2013
Yearly, From 2003 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu
- Industries : Pharmaceutical
- Countries : Portugal, Europe
